AbbVie (ABBV)
256.46
-3.75 (1.44%)
Upcoming Events
Latest Headlines
AbbVie's etentamig meets Phase 3 endpoints in multiple myeloma trial
September 3, 2026 9:15 AM - StreetInsider
AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multi
September 3, 2026 9:15 AM - PR NewsWire
Form 8-K AbbVie Inc. For: Sep 03
September 3, 2026 8:48 AM - SEC Filing
AbbVie completes $10.9B acquisition of Apogee Therapeutics
September 3, 2026 8:35 AM - StreetInsider
AbbVie Completes Acquisition of Apogee Therapeutics
September 3, 2026 8:35 AM - PR NewsWire
AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
September 3, 2026 8:05 AM - PR NewsWire
Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care
September 2, 2026 8:00 AM - PR NewsWire
SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings
September 1, 2026 8:05 AM - PR NewsWire
AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference
August 31, 2026 8:00 AM - PR NewsWire
AbbVie seeks EMA approval for Skyrizi subcutaneous use in Crohn's
August 27, 2026 6:00 AM - StreetInsider
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
August 27, 2026 2:00 AM - PR NewsWire
AbbVie lung cancer drug data shows high response rates at WCLC 2026
August 21, 2026 7:45 AM - StreetInsider
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
August 21, 2026 7:45 AM - PR NewsWire
Abbvie (ABBV) PT Raised to $303 at Piper Sandler
August 20, 2026 7:22 AM - StreetInsider
Form 4 AbbVie Inc. For: Aug 14 Filed by: Donoghoe Nicholas
August 18, 2026 5:00 PM - SEC Filing
Form 8-K AbbVie Inc. For: Aug 18
August 18, 2026 4:31 PM - SEC Filing
A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
August 18, 2026 12:57 PM - Globe NewsWire
AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
August 18, 2026 8:00 AM - PR NewsWire
Abbvie (ABBV) PT Raised to $300 at Wells Fargo
August 17, 2026 6:26 AM - StreetInsider
Form 144 AbbVie Inc. Filed by: Donoghoe Nicholas
August 14, 2026 4:40 PM - SEC Filing
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
August 13, 2026 9:26 AM - StreetInsider
Wolfe Research Upgrades Abbvie (ABBV) to Outperform
August 13, 2026 5:35 AM - StreetInsider
The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
August 12, 2026 9:15 AM - StreetInsider
Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices
August 11, 2026 8:01 AM - PR NewsWire
Form 424B5 AbbVie Inc.
August 6, 2026 5:08 PM - SEC Filing
Form 8-K AbbVie Inc. For: Aug 04
August 5, 2026 5:17 PM - SEC Filing
Erste Group Upgrades Abbvie (ABBV) to Buy
August 5, 2026 9:51 AM - StreetInsider
Form FWP AbbVie Inc. Filed by: AbbVie Inc.
August 5, 2026 6:04 AM - SEC Filing
Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
August 4, 2026 9:05 AM - StreetInsider
Form 424B5 AbbVie Inc.
August 4, 2026 8:19 AM - SEC Filing
FDA accepts AbbVie's Botox Cosmetic application for jaw slimming use
August 4, 2026 8:01 AM - StreetInsider
Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence
August 4, 2026 8:00 AM - PR NewsWire
Abbvie (ABBV) PT Raised to $288 at Guggenheim
August 4, 2026 6:49 AM - StreetInsider
Form 10-Q AbbVie Inc. For: Jun 30
August 3, 2026 2:14 PM - SEC Filing
Abbvie (ABBV) PT Raised to $285 at Cantor Fitzgerald
August 3, 2026 9:19 AM - StreetInsider
Abbvie (ABBV) PT Raised to $296 at Morgan Stanley
August 3, 2026 8:17 AM - StreetInsider
Abbvie (ABBV) PT Raised to $290 at Canaccord
August 3, 2026 6:41 AM - StreetInsider
U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
August 1, 2026 10:00 AM - StreetInsider
AbbVie shares fall on earnings miss and weak guidance
July 31, 2026 8:12 AM - StreetInsider
Form 8-K AbbVie Inc. For: Jul 31
July 31, 2026 7:51 AM - SEC Filing
AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
July 31, 2026 7:49 AM - StreetInsider
AbbVie Reports Second-Quarter 2026 Financial Results
July 31, 2026 7:47 AM - PR NewsWire
AbbVie Q2 earnings preview: analysts eye immunology growth, pipeline
July 30, 2026 11:30 PM - StreetInsider
AbbVie (ABBV) call put ratio 1 call to 1 put into quarter results
July 30, 2026 11:01 AM - StreetInsider
JUVÉDERM® Day Returns to U.S. on August 19
July 30, 2026 8:00 AM - PR NewsWire
Abbvie (ABBV) PT Raised to $300 at Barclays
July 29, 2026 5:19 AM - StreetInsider
EU approves AbbVie's Rinvoq for severe alopecia areata
July 29, 2026 3:00 AM - StreetInsider
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
July 29, 2026 3:00 AM - PR NewsWire
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
July 29, 2026 3:00 AM - PR NewsWire
Genmab and AbbVie say epcoritamab trial missed U.S. survival goal
July 23, 2026 4:00 PM - StreetInsider
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
July 23, 2026 4:00 PM - StreetInsider
Abbvie (ABBV) PT Raised to $282 at Canaccord
July 22, 2026 6:39 AM - StreetInsider
EU approves AbbVie's Boey for short-duration frown line treatment
July 17, 2026 8:03 AM - StreetInsider
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in ad
July 17, 2026 8:00 AM - PR NewsWire
Abbvie (ABBV) PT Raised to $260 at Citi
July 15, 2026 5:02 AM - StreetInsider
SkinMedica launches advisory board and expands R&D lab in Irvine
July 14, 2026 8:05 AM - StreetInsider
SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
July 14, 2026 8:05 AM - PR NewsWire
Abbvie (ABBV) PT Raised to $300 at BMO Capital
July 13, 2026 7:31 AM - StreetInsider
Abbvie (ABBV) PT Raised to $280 at RBC Capital
July 10, 2026 7:30 AM - StreetInsider
Abbvie (ABBV) PT Raised to $295 at Wells Fargo
July 10, 2026 6:35 AM - StreetInsider
Abbvie (ABBV) PT Raised to $280 at JPMorgan
July 9, 2026 7:59 AM - StreetInsider
Abbvie (ABBV) PT Raised to $261 at Guggenheim
July 9, 2026 7:09 AM - StreetInsider
AbbVie updates 2026 EPS guidance after $291M IPR&D charge
July 6, 2026 4:14 PM - StreetInsider
Form 8-K AbbVie Inc. For: Jul 06
July 6, 2026 4:12 PM - SEC Filing
EU approves AbbVie's Tepkinly combo for follicular lymphoma
July 6, 2026 1:45 PM - StreetInsider
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
July 6, 2026 1:45 PM - PR NewsWire
Abbvie (ABBV) PT Raised to $265 at Cantor Fitzgerald: Broadly Strong Q2 Results Expected
July 6, 2026 6:43 AM - StreetInsider
Abbvie (ABBV) PT Raised to $300 at HSBC
July 6, 2026 1:34 AM - StreetInsider
Form 4 AbbVie Inc. For: Jul 01 Filed by: RAPP EDWARD J
July 2, 2026 5:01 PM - SEC Filing
Form 4 AbbVie Inc. For: Jun 30 Filed by: Quaggin Susan E
July 2, 2026 5:00 PM - SEC Filing
A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
July 1, 2026 9:05 AM - StreetInsider
RBC Capital Reiterates Outperform Rating on Abbvie (ABBV)
July 1, 2026 8:01 AM - StreetInsider
U.S. House committee opens investigation into Merck, AbbVie China drug trials - Reuters
June 30, 2026 6:02 AM - StreetInsider
FDA selects 7 companies for domestic drug manufacturing pilot
June 29, 2026 4:20 PM - StreetInsider
AbbVie's epcoritamab combo meets primary endpoint in lymphoma trial
June 29, 2026 4:15 PM - StreetInsider
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
June 29, 2026 4:15 PM - PR NewsWire
AbbVie's Rinvoq gets positive EU panel opinion for hair loss
June 29, 2026 3:10 AM - StreetInsider
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
June 29, 2026 3:10 AM - PR NewsWire
EU panel backs AbbVie's Rinvoq for vitiligo treatment
June 29, 2026 3:00 AM - StreetInsider
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
June 29, 2026 3:00 AM - PR NewsWire
FDA approves AbbVie's Skyrizi for children with psoriatic disease
June 26, 2026 4:52 PM - StreetInsider
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
June 26, 2026 4:51 PM - PR NewsWire
AbbVie to Host Second-Quarter 2026 Earnings Conference Call
June 26, 2026 8:00 AM - PR NewsWire
The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for It
June 25, 2026 9:04 AM - StreetInsider
Form 11-K AbbVie Inc. For: Dec 31
June 24, 2026 5:27 PM - SEC Filing
BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026
June 24, 2026 8:00 AM - PR NewsWire
Bernstein SocGen's Thoughts on Abbvie (ABBV) Following APGE Acquisition
June 23, 2026 9:12 AM - StreetInsider
Health Canada approves AbbVie's Boey for frown line treatment
June 23, 2026 8:00 AM - StreetInsider
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patie
June 23, 2026 8:00 AM - PR NewsWire
Abbvie (ABBV) Reiterated at Overweight by Cantor Fitzgerald after Analyst Call
June 23, 2026 7:22 AM - StreetInsider
Abbvie (ABBV) PT Raised to $273 at Canaccord
June 23, 2026 7:06 AM - StreetInsider
EU approves AbbVie's Maviret for acute hepatitis C treatment
June 23, 2026 5:39 AM - StreetInsider
AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
June 23, 2026 5:00 AM - PR NewsWire
EU approves AbbVie's Skyrizi for children with plaque psoriasis
June 23, 2026 4:09 AM - StreetInsider
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
June 23, 2026 3:00 AM - PR NewsWire
Apogee Therapeutics, BitFuFu rise premarket; AbbVie gains after deal
June 22, 2026 10:16 AM - StreetInsider
Form 8-K AbbVie Inc. For: Jun 18
June 22, 2026 7:11 AM - SEC Filing
AbbVie sharpens immunology focus with $10.9 billion Apogee deal
June 22, 2026 7:09 AM - StreetInsider
AbbVie agrees to acquire Apogee Therapeutics for $10.9 billion
June 22, 2026 7:01 AM - StreetInsider
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
June 22, 2026 7:00 AM - PR NewsWire
AbbVie (ABBV) call put ratio 2.2 calls to 1 put into near deal to acquire Apogee Therapeutics (APGE), FT reports
June 22, 2026 6:23 AM - StreetInsider
AbbVie (ABBV) Declares $1.73 Quarterly Dividend; 3.2% Yield
June 18, 2026 4:07 PM - StreetInsider
AbbVie Declares Quarterly Dividend
June 18, 2026 4:06 PM - PR NewsWire
Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
June 16, 2026 8:15 AM - PR NewsWire
FDA approves ABBVIE neck wrinkle injectable SKINVIVE by JUVÉDERM
June 16, 2026 8:01 AM - StreetInsider
Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
June 16, 2026 8:00 AM - PR NewsWire
Leerink highlights drug demand rebound after Memorial Day
June 12, 2026 2:42 PM - StreetInsider
AbbVie presents nine-year venetoclax trial results at EHA congress
June 12, 2026 3:03 AM - StreetInsider
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Resu
June 12, 2026 3:00 AM - PR NewsWire
Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics
June 10, 2026 8:00 AM - PR NewsWire
AbbVie to present blood cancer data at EHA 2026
June 8, 2026 8:01 AM - StreetInsider
AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
June 8, 2026 8:00 AM - PR NewsWire
Full Article List
